Liquid biopsy is the practice of looking for tumor-related material in blood or other body fluids rather than relying only on a surgical or needle tissue sample. Depending on the assay, that can include circulating tumor DNA, cell-free DNA methylation patterns, circulating tumor cells, RNA fragments, proteins, exosomes, or other molecular traces released by cancer.
Why It Matters
Liquid biopsy matters because it can be repeated more easily than tissue biopsy and may capture disease changes over time. In oncology, that makes it useful for molecular residual disease assessment, treatment-response monitoring, emerging resistance detection, and cases where tissue is limited or difficult to obtain safely.
It is not a perfect substitute for tissue pathology, but it can provide a faster and less invasive view of how a tumor is evolving between scans or between procedures.
Where AI Fits
AI helps liquid-biopsy workflows by separating very low-frequency tumor signal from noise, combining fragmentomics or methylation patterns across many features, and linking those signals to treatment response or relapse risk. That is why liquid biopsy increasingly overlaps with multimodal learning, especially when blood-derived measurements are interpreted together with imaging, pathology, and clinical history.
Good liquid-biopsy systems still depend on strong ground truth, careful assay calibration, and realistic handling of uncertainty. Tumor fraction can be very low, and confounders such as clonal hematopoiesis can make weak signals look more specific than they really are.
Related Yenra articles: Precision Oncology and Targeted Therapies, Biomarker Discovery in Healthcare, Cancer Treatment Planning, and Personalized Medicine.
Related concepts: Multimodal Learning, Ground Truth, Uncertainty, and Digital Biomarker.